
Roman Casciano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5785981/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort. Clinical Infectious Diseases, 2022, 75, e450-e458.	5.8	84
2	Clinical Management of Hospitalized Coronavirus Disease 2019 Patients in the United States. Open Forum Infectious Diseases, 2022, 9, .	0.9	2
3	Comparative effectiveness research in COVID-19 using real-world data: methodological considerations. Journal of Comparative Effectiveness Research, 2021, 10, 1259-1264.	1.4	2
4	Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 243-250.	1.9	18
5	Treatment patterns among patients with metastatic GEP-NET treated at a tertiary referral center Journal of Clinical Oncology, 2017, 35, 397-397.	1.6	1
6	First-Year Incidence of Double-Stranded DNA Virus Infections Following Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S169.	2.0	0
7	Clinical and Economic Consequences Associated with Cytomegalovirus Infection Among Allogeneic Hematopoietic Cell Transplant Patients. Biology of Blood and Marrow Transplantation, 2016, 22, S160.	2.0	0
8	First-Year Incidence of Adenovirus Infections Following Allogeneic Hematopoietic Cell Transplants in a Pediatric Population. Biology of Blood and Marrow Transplantation, 2016, 22, S170-S171.	2.0	2
9	An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. Clinical Therapeutics, 2015, 37, 2552-2559.	2.5	13
10	A weighted-adjusted indirect comparison of everolimus (EVE) versus axitinib (AXI) in second-line metastatic renal cell carcinoma (mRCC) patients who previously failed sunitinib therapy Journal of Clinical Oncology, 2014, 32, 491-491.	1.6	1
11	Health plan budget impact of introducing everolimus for treatment of advanced progressive pancreatic neuroendocrine tumors in the United States Journal of Clinical Oncology, 2012, 30, 229-229.	1.6	0
12	Cost-effectiveness of treating patients with advanced progressive pancreatic neuroendocrine tumor with everolimus versus sunitinib in the United States Journal of Clinical Oncology, 2012, 30, 226-226.	1.6	0
13	Resource utilization among neuroendocrine tumor patients in the United States Journal of Clinical Oncology, 2012, 30, 251-251.	1.6	1
14	The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clinical Therapeutics, 2008, 30, 341-357.	2.5	37
15	P176: Burden of Chronic Sinusitis: A Survey of Otolaryngologists. Otolaryngology - Head and Neck Surgery, 2006, 135, P270-P270.	1.9	0
16	P182: Amphotericin B Nasal Spray in Chronic Sinusitis Chart Review. Otolaryngology - Head and Neck Surgery, 2006, 135, P272-P272.	1.9	0
17	A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain. Value in Health, 2004, 7, 36-51.	0.3	42
18	A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain. European Journal of Health Economics, 2004, 5, 278-284.	2.8	14

ROMAN CASCIANO

#	Article	IF	CITATIONS
19	A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden. International Journal of Cardiology, 2004, 96, 51-57.	1.7	12
20	Cost and Effectiveness of Venlafaxine Extended-Release and Selective Serotonin Reuptake Inhibitors in the Acute Phase of Outpatient Treatment for Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2004, 24, 497-506.	1.4	23
21	A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. Pharmacoeconomics, 2003, 21, 25-32.	3.3	19
22	A Pharmacoeconomic Evaluation of 7â€Valent Pneumococcal Conjugate Vaccine in Canada. Clinical Infectious Diseases, 2003, 36, 259-268.	5.8	52
23	Economic Benefits of Amlodipine Treatment in Patients with Coronary Artery Disease. Pharmacoeconomics, 2002, 20, 553-563.	3.3	6
24	A pharmacoeconomic evaluation of results from the coronary angioplasty amlodipine restenosis study (CAPARES) in Norway and Canada. International Journal of Cardiology, 2002, 84, 23-30.	1.7	9
25	A Multinational Pharmacoeconomic Evaluation of Acute Major Depressive Disorder (MDD): a Comparison of Cost-Effectiveness Between Venlafaxine, SSRIs and TCAs. Value in Health, 2001, 4, 16-31.	0.3	52
26	A pharmacoeconomic evaluation of major depressive disorder (Italy). Epidemiologia E Psichiatria Sociale, 1999, 8, 220-231.	0.9	6